Drug Profile
Autologous osteoblastic cell therapy - BioSenic
Alternative Names: Autologous-osteoblastic-cells-BioSenic; Autologous-pre-osteoblast-cell-therapy-BioSenic; Autologous-pre-osteoblastic-cell-therapy-BioSenic; Autologous-preosteoblastic-cells-BioSenic; PREOB; PREOB cells; PREOB-NU; PREOB-ONLatest Information Update: 03 Nov 2022
Price :
$50
*
At a glance
- Originator Bone Therapeutics
- Developer BioSenic
- Class Cell therapies
- Mechanism of Action Cell replacements; Osteogenesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Femur head necrosis; Non-union fracture; Osteoporosis
Most Recent Events
- 25 Oct 2022 Medsenic has been acquired by Bone Therapeutics and the later changed its name to BioSenic
- 06 Nov 2018 Bone Therapeutics terminates phase III trial in Femur head necrosis in United Kingdom, Belgium, France, Germany and Netherlands as per the recommendation from the DSMB
- 20 Oct 2017 Bone Therapeutics terminates a phase II/III trial in Non-union fracture in Belgium, France and Netherlands to focus resources in the allogeneic platform and provide optimal value for patients (Intraosseous) (NCT01756326)